These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24392984)

  • 1. Adaptive designs for confirmatory clinical trials with subgroup selection.
    Stallard N; Hamborg T; Parsons N; Friede T
    J Biopharm Stat; 2014; 24(1):168-87. PubMed ID: 24392984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On sample size determination in multi-armed confirmatory adaptive designs.
    Wassmer G
    J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designing Issues in Confirmatory Adaptive Population Enrichment Trials.
    Wassmer G; Dragalin V
    J Biopharm Stat; 2015; 25(4):651-69. PubMed ID: 24905739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of statistical and regulatory issues in the planning, analysis, and interpretation of subgroup analyses in confirmatory clinical trials.
    Hemmings R
    J Biopharm Stat; 2014; 24(1):4-18. PubMed ID: 24392975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive methods: when and how should they be used in clinical trials?
    Porcher R; Lecocq B; Vray M;
    Therapie; 2011; 66(4):319-26, 309-17. PubMed ID: 21851793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R.
    Friede T; Stallard N; Parsons N
    Biom J; 2020 Sep; 62(5):1264-1283. PubMed ID: 32118317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
    Schmidli H; Bretz F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
    Bauer P; Bretz F; Dragalin V; König F; Wassmer G
    Stat Med; 2016 Feb; 35(3):325-47. PubMed ID: 25778935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple and flexible graphical approach for adaptive group-sequential clinical trials.
    Sugitani T; Bretz F; Maurer W
    J Biopharm Stat; 2016; 26(2):202-16. PubMed ID: 25372071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A consultant's perspective on the regulatory hurdles to adaptive trials.
    Mehta CR; Jemiai Y
    Biom J; 2006 Aug; 48(4):604-8; discussion 613-22. PubMed ID: 16972712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival endpoints and adaptive designs.
    Bauer P
    Biom J; 2006 Aug; 48(4):730-1. PubMed ID: 16972725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive methods: telling "the rest of the story".
    Emerson SS; Fleming TR
    J Biopharm Stat; 2010 Nov; 20(6):1150-65. PubMed ID: 21058111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis.
    Chataway J; Nicholas R; Todd S; Miller DH; Parsons N; Valdés-Márquez E; Stallard N; Friede T
    Mult Scler; 2011 Jan; 17(1):81-8. PubMed ID: 20798135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
    Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
    Trials; 2011 Mar; 12():81. PubMed ID: 21418571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Probabilities of Correct Interim Decision in Population Enrichment Designs.
    Götte H; Donica M; Mordenti G
    J Biopharm Stat; 2015; 25(5):1020-38. PubMed ID: 24914474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.
    Ondra T; Dmitrienko A; Friede T; Graf A; Miller F; Stallard N; Posch M
    J Biopharm Stat; 2016; 26(1):99-119. PubMed ID: 26378339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.